Medicare this week began covering GLP-1 drugs prescribed for weight loss, a policy shift that makes millions of Americans newly eligible for the benefit. The program had previously limited GLP-1 coverage to patients diagnosed with Type 2 diabetes, sleep apnea, or elevated cardiovascular risk tied to a prior stroke or heart attack.
The Diagnosis Gate That Has Now Lifted
Until this week, a Medicare enrollee could access GLP-1 coverage under one of three qualifying diagnoses only: Type 2 diabetes, sleep apnea, or documented stroke or heart-attack risk. Patients whose primary condition was obesity — without one of those concurrent diagnoses — had no coverage pathway through the program for the drug class. The new policy adds weight loss as a standalone qualifying use, removing the prior diagnostic requirement.
Who Is Now Eligible — and What Stays the Same
The policy change extends GLP-1 weight-loss coverage to millions of Medicare enrollees for the first time. The three earlier coverage categories — Type 2 diabetes, sleep apnea, and cardiovascular risk — remain intact alongside the new weight-loss pathway. Beneficiaries now have access to coverage starting this week, and cost remains a relevant consideration for those entering through the expanded criteria.